Merck Sharp + Dohme Corp.

Schering Corporation

Li Xiao

Alexander Pasternak

Yongxin Han

Vincent Stewart Madison

Shuzhi Dong

Jinlong Jiang

Shuwen He

Liangqin Guo

Xin Gu

Jack D Scott

Guoqing Li

Neng-Yang Shih

Frank W Bennett

Xianhai Huang

Wensheng Yu

Hongjun Zhang

Paul Reichert

Jianmin Fu

Ping Chen

Thierry Olivier Fischmann

Ronald J Doll

Joseph A Kozlowski

William K Hagmann

Brian Alexander McKittrick

M Arshad Siddiqui

Alan B Cooper

Joseph Michael Kelly

Gerald Wayne Shipps, Jr

Fa-Xiang Ding

Haifeng Tang

Tin-Yau Chan

Alan W Hruza

Jing Su

Yongqi Deng

Xu Zhang

Stephane L Bogen

Jongwon Lim

David J Blythin

Dong Xiao

Ying Huang

Corey Strickland

David L Sloman

Pauline C Ting

Michael T Rudd

Sunil Paliwal

Ho-Jane Shue

Nunzio Sciammetta

Peter Orth

Tong Wang

Dane James Clausen

Dexi Yang

Haiqun Tang

Xavier Fradera

Zhiqiang Zhao

Yuhua Huang

Andrew Joseph Prongay

Katherine Young

Feng Ye

Zhibo Zhang

Hung V Le

Qinglin Pu

Weidong Pan

William T Windsor

Jagdish A Desai

Robert Sun

Shahriar Shane Taremi

Mihir Mandal

James J-s Wang

Hugh Y Zhu

Winifred W Prosise

Shu-Wei Yang

Wenyan Wang

Rui Zhang

Yang Nan

Youhao Dong

Haiyan Pu

Rongze Kuang

Xiao Chen

Xiaolei Gao

Hon-Chung Tsui

Clare London

Nicholas J Murgolo

Jacqueline D Hicks

Lan Wei

Jianping Pan

Ahmed Abdi Samatar

Deodial Guy Guiadeen

Sobhana Babu Boga

Mehul F Patel

Jinsong Hao

Jianhua Cao

Liang Zhu

John H Schwerdt

Gerald W Shipps

Abdul-Basit Alhassan

Zhixiang Zheng

Andreas Verras

Hong Dong Chu

Yunfeng Bai

Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

Substituted piperazine amide compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors

Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

Arylalkyl pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors

Substituted pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors

Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

Substituted tetrahydroquinoline compounds as indoleamine 2,3-dioxygenase inhibitors

The present invention is directed to bicyclo[4.1.0]heptane pyrrolidine compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.

Bicycloheptane pyrrolidine orexin receptor agonists

Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder. 

[1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors

Substituted [1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors

The present invention relates to metallo-&#x3b2;-lactamase inhibitor compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein Z, R, X, Xand Rare as defined herein. The present invention also relates to compositions which comprise a metallo-&#x3b2;-lactamase inhibitor compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination with a beta lactam antibiotic and/or a beta-lactamase inhibitor. The invention further relates to methods for treating a bacterial infection comprising administering to a patient a therapeutically effective amount of a compound of the invention, in combination with a therapeutically effective amount of one or more &#x3b2;-lactam antibiotics and optionally in combination with one or more beta-lactamase inhibitor compounds. The compounds of the invention are useful in the methods described herein for overcoming antibiotic resistance. 

Metallo-beta-lactamase inhibitors and methods of use thereof

The present invention relates to metallo-&#x3b2;-lactamase inhibitor compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein Z, R, X, Xand Rare as defined herein. The present invention also relates to compositions which comprise a metallo-&#x3b2;-lactamase inhibitor compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination with a beta lactam antibiotic and/or a beta-lactamase inhibitor. The invention further relates to methods for treating a bacterial infection comprising administering to a patient a therapeutically effective amount of a compound of the invention, in combination with a therapeutically effective amount of one or more &#x3b2;-lactam antibiotics and optionally in combination with one or more beta-lactamase inhibitor compounds. The compounds of the invention are useful in the methods described herein for overcoming antibiotic resistance.

Metallo-beta-lactamase inhibitors

The present invention relates to metallo-&#x3b2;-lactamase inhibitor compounds of Formula I: (I) and pharmaceutically acceptable salts thereof, wherein Z, R, X, Xand Rare as defined herein. The present invention also relates to compositions which comprise a metallo-&#x3b2;-lactamase inhibitor compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination with a beta lactam antibiotic and/or a beta-lactamase inhibitor. The invention further relates to methods for treating a bacterial infection comprising administering to a patient a therapeutically effective amount of a compound of the invention, in combination with a therapeutically effective amount of one or more &#x3b2;-lactam antibiotics and optionally in combination with one or more beta-lactamase inhibitor compounds. The compounds of the invention are useful in the methods described herein for overcoming antibiotic resistance. 

Metallo-&#x3b2;-lactamase inhibitors

The present invention relates to metallo-beta-lactamase inhibitor compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein Z, R, X, Xand Rare as defined herein. The present invention also relates to compositions which comprise a metallo-beta-lactamase inhibitor compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination with a beta-lactam antibiotic and/or a beta-lactamase inhibitor. The invention further relates to methods for treating a bacterial infection comprising administering to a patient a therapeutically effective amount of a compound of the invention, in combination with a therapeutically effective amount of one or more &#x3b2;-lactam antibiotics and optionally in combination with one or more beta-lactamase inhibitor compounds. The compounds of the invention are useful in the methods described herein for overcoming antibiotic resistance. 

The present invention relates to compounds of formula I that are metallo-&#x3b2;-lactamase inhibitors, the synthesis of such compounds, and the use of such compounds for use with &#x3b2;-lactam antibiotics for overcoming resistance. 

Beta-tetrazolyl-propionic acids as metallo-beta-lactamase inhibitors

The present invention relates to compounds of formula (I) that are metallo-&#x3b2;-lactamase inhibitors, the synthesis of such compounds, and the use of such compounds for use with &#x3b2;-lactam antibiotics for overcoming resistance. 

The present invention provides polypeptide domains oftoxin B (B1, B2, B3, B4) and complexes between the polypeptides and antibodies that bind specifically for the polypeptide. Methods of using the polypeptides to generate antibodies are also provided.

C.difficile toxin B CROP domain peptides, antibodies and complexes thereof

Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts, esters and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.

Compounds that are ERK inhibitors

Growing community of inventors

Cranbury, NJ, United States of America

Li Xiao